Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.
Protease inhibitors (PIs) have been implicated in the development of HIV-associated lipodystrophy through a reduction in the differentiation of preadipocytes. While atazanavir (ATV) is associated with fewer clinical metabolic abnormalities in the short-term, the effects of long-term exposure are not known. ATV effects on preadipocyte replication or differentiation would indicate the potential for long-term problems. This study compared ritonavir (RTV) and ATV effects on preadipocyte replication and differentiation in human primary cultures. Preadipocytes from subcutaneous fat were studied in the presence of therapeutic concentrations of RTV and ATV for replication, differentiation, and adipokine secretion. The effects of the drugs on the expression of PPARgamma and related genes during differentiation were also assessed by real-time quantitative PCR. RTV induced a significant inhibition of preadipocyte proliferation, differentiation and adiponectin secretion. ATV at concentrations within the range of therapeutic levels did not affect differentiation or adiponectin secretion, but did have inhibitory effects on preadipocyte proliferation. Inhibition of differentiation by PIs was associated with decreased expression of PPARgamma, C/EBPalpha, and aP2 genes. In summary, although ATV at therapeutic levels has a smaller impact on adipogenesis, alterations in preadipocyte proliferation suggest the potential for adverse effects with long-term use.
Caso
Giuseppe
G
Department of Surgery, Stony Brook University Medical Center, Stony Brook, NY 11794-8191, USA. Giuseppe.Caso@stonybrook.edu
Mileva
Izolda
I
McNurlan
Margaret A
MA
Mynarcik
Dennis C
DC
Darras
Frank
F
Gelato
Marie C
MC
D017667:Adipocytes / Q000187:drug effects*; D052242:Adiponectin / Q000378:metabolism; D000328:Adult; D019380:Anti-HIV Agents / Q000633:toxicity*; D000069446:Atazanavir Sulfate; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D050556:Fatty Acid-Binding Proteins / Q000096:biosynthesis; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000633:toxicity*; D047495:PPAR gamma / Q000096:biosynthesis; D011725:Pyridines / Q000633:toxicity*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019438:Ritonavir / Q000633:toxicity*
D052242:Adiponectin; D019380:Anti-HIV Agents; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D009842:Oligopeptides; D047495:PPAR gamma; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019438:Ritonavir